Short answer
Emergent BioSolutions Inc. (EBS) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Q4 and full-year 2025 earnings released Feb 26, 2026; full results in Exhibit 99.1.
Emergent BioSolutions Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 earnings released Feb 26, 2026; full results in Exhibit 99.1
- EBS reporting period covers quarter and fiscal year ended Dec 31, 2025
Item 7.01 · Regulation FD Disclosure
- Earnings call scheduled Feb 26, 2026 to discuss Q4 and full-year 2025 financial results
- Presentation slides (Exhibit 99.2) posted to company website ahead of call: key source for operational metrics and guidance
- Disclosure furnished, not filed: limits legal liability under Exchange Act Section 18
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Emergent BioSolutions Inc. 8-K filings
Get the next EBS 8-K as it lands
Follow EBS for push alerts, or ask the research agent what this filing means.